Capmatinib in patients with METex14-mutated or high-level MET-amplified advanced non-small- cell lung cancer (NSCLC): results from cohort 6 of the phase 2 GEOMETRY mono-1 study

J. Wolf; H. J. M. Groen; W. Akerley; P. -J. Souquet; E. Laack; J. -Y. Han; E. F. Smit; A. S. Mansfield; E. B. Garon; D. S. W. Tan; R. S. Heist; M. Waldron-Lynch; S. Le Mouhaer; N. Nwana; M. Giovannini; S. Orlov

doi:10.1200/JCO.2020.38.15_suppl.9520

Capmatinib in patients with METex14-mutated or high-level MET-amplified advanced non-small- cell lung cancer (NSCLC): results from cohort 6 of the phase 2 GEOMETRY mono-1 study

J. Wolf, H. J. M. Groen, W. Akerley, P. -J. Souquet, E. Laack, J. -Y. Han, E. F. Smit, A. S. Mansfield, E. B. Garon, D. S. W. Tan, R. S. Heist, M. Waldron-Lynch, S. Le Mouhaer, N. Nwana, M. Giovannini, S. Orlov

Research output: Contribution to journal › Meeting Abstract › Academic

Original language	English
Pages (from-to)	143-143
Number of pages	1
Journal	Oncology Research and Treatment
Volume	43
Issue number	SUPPL 4
DOIs	https://doi.org/10.1200/JCO.2020.38.15_suppl.9520
Publication status	Published - Oct-2020

Access to Document

10.1200/JCO.2020.38.15_suppl.9520

Handle.net

Persistent link

Cite this

Wolf, J., Groen, H. J. M., Akerley, W., Souquet, P. .-J., Laack, E., Han, J. .-Y., Smit, E. F., Mansfield, A. S., Garon, E. B., Tan, D. S. W., Heist, R. S., Waldron-Lynch, M., Le Mouhaer, S., Nwana, N., Giovannini, M., & Orlov, S. (2020). Capmatinib in patients with METex14-mutated or high-level MET-amplified advanced non-small- cell lung cancer (NSCLC): results from cohort 6 of the phase 2 GEOMETRY mono-1 study. Oncology Research and Treatment, 43(SUPPL 4), 143-143. https://doi.org/10.1200/JCO.2020.38.15_suppl.9520

@article{beb031bfc3944a0cb9f49cb4561e3f00,

title = "Capmatinib in patients with METex14-mutated or high-level MET-amplified advanced non-small- cell lung cancer (NSCLC): results from cohort 6 of the phase 2 GEOMETRY mono-1 study",

author = "J. Wolf and Groen, {H. J. M.} and W. Akerley and Souquet, {P. -J.} and E. Laack and Han, {J. -Y.} and Smit, {E. F.} and Mansfield, {A. S.} and Garon, {E. B.} and Tan, {D. S. W.} and Heist, {R. S.} and M. Waldron-Lynch and {Le Mouhaer}, S. and N. Nwana and M. Giovannini and S. Orlov",

year = "2020",

month = oct,

doi = "10.1200/JCO.2020.38.15_suppl.9520",

language = "English",

volume = "43",

pages = "143--143",

journal = "Oncology Research and Treatment",

issn = "2296-5270",

publisher = "KARGER",

number = "SUPPL 4",

}

Wolf, J, Groen, HJM, Akerley, W, Souquet, P-J, Laack, E, Han, J-Y, Smit, EF, Mansfield, AS, Garon, EB, Tan, DSW, Heist, RS, Waldron-Lynch, M, Le Mouhaer, S, Nwana, N, Giovannini, M & Orlov, S 2020, 'Capmatinib in patients with METex14-mutated or high-level MET-amplified advanced non-small- cell lung cancer (NSCLC): results from cohort 6 of the phase 2 GEOMETRY mono-1 study', Oncology Research and Treatment, vol. 43, no. SUPPL 4, pp. 143-143. https://doi.org/10.1200/JCO.2020.38.15_suppl.9520

Capmatinib in patients with METex14-mutated or high-level MET-amplified advanced non-small- cell lung cancer (NSCLC): results from cohort 6 of the phase 2 GEOMETRY mono-1 study. / Wolf, J.; Groen, H. J. M.; Akerley, W. et al.
In: Oncology Research and Treatment, Vol. 43, No. SUPPL 4, 10.2020, p. 143-143.

Research output: Contribution to journal › Meeting Abstract › Academic

TY - JOUR

T1 - Capmatinib in patients with METex14-mutated or high-level MET-amplified advanced non-small- cell lung cancer (NSCLC)

T2 - results from cohort 6 of the phase 2 GEOMETRY mono-1 study

AU - Wolf, J.

AU - Groen, H. J. M.

AU - Akerley, W.

AU - Souquet, P. -J.

AU - Laack, E.

AU - Han, J. -Y.

AU - Smit, E. F.

AU - Mansfield, A. S.

AU - Garon, E. B.

AU - Tan, D. S. W.

AU - Heist, R. S.

AU - Waldron-Lynch, M.

AU - Le Mouhaer, S.

AU - Nwana, N.

AU - Giovannini, M.

AU - Orlov, S.

PY - 2020/10

Y1 - 2020/10

U2 - 10.1200/JCO.2020.38.15_suppl.9520

DO - 10.1200/JCO.2020.38.15_suppl.9520

M3 - Meeting Abstract

SN - 2296-5270

VL - 43

SP - 143

EP - 143

JO - Oncology Research and Treatment

JF - Oncology Research and Treatment

IS - SUPPL 4

ER -